Method of inhibiting activation of a T cell by administering an anti-RGM antibody or an RGM siRNA
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsToshihide Yamashita, Takekazu Kubo
Life of this patent
Estimating the term…
Abstract
Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.
Claims20
An in vivo method of inhibiting activation of a T cell by a Repulsive Guidance Molecule (RGM) expressing cell, comprising
- a step of contacting an RGM inhibiting substance with an RGM expressing cell in a patient that has rheumatism, multiple sclerosis, Guillain-Barré syndrome, neuro-Behcet's disease, malignant anemia, type I (insulin-dependent) diabetes, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), Sjogren's syndrome, atopic dermatitis, Goodpasture's syndrome, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, glomerulonephritis, myasthenia gravis, or Hashimoto's disease,
- wherein the RGM inhibiting substance is an anti-RGM neutralizing antibody or an RGM siRNA,
- thereby inhibiting activation of a T cell by the RGM expressing cell.
Dependencies are inferred from the claim text.